𝔖 Bobbio Scriptorium
✦   LIBER   ✦

ChemInform Abstract: The Treatment of Dyslipidemia — What′s Left in the Pipeline?

✍ Scribed by Oliver Rau; Heiko Zettl; Laura Popescu; Dieter Steinhilber; Manfred Schubert-Zsilavecz

Publisher
John Wiley and Sons
Year
2008
Weight
11 KB
Volume
39
Category
Article
ISSN
0931-7597

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

📜 SIMILAR VOLUMES

Pravastatin compared to bezafibrate in t
Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus
✍ C. Rustemeijer; J. A. Schouten; H. J. Voerman; H. E. S. J. Hensgens; A. J. M. Do 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

Background Both HMG-CoA reductase inhibitors and ®bric acid derivates are used for the treatment of dyslipidemia in Type 2 diabetes patients. The aim of this study was to compare the lipid lowering effect of 40 mg pravastatin, a HMG-CoA reductase inhibitor, and 400 mg beza®brate, a ®bric acid deriva